Fig. S1. Patient disposition through Week 52 of IXORA-Q. During study Weeks 24, 28, and 40, 52 patients increased dosing frequency from 80 mg ixekizumab every 4 weeks up to 80 mg ixekizumab every 2 weeks until the end of the study. Of these, 27 patients were initially randomized to placebo and 25 were initially randomized to 80 mg ixekizumab every 2 weeks.